Tissue-selective agents: Selective estrogen receptor modulators and the tissue-selective estrogen complex

Menopause International

Volumn 16, Issue 3, 2010, Pages 121-128

  Pickar, James H ^a   Mirkin, Sebastián ^b  

^a NewYork Presbyterian Hospital   (United States)

^b PFIZER INC   (United States)

Author keywords

Estrogen; Menopause; Selective estrogen receptor modulator; Tissue selective estrogen complex

Indexed keywords

BAZEDOXIFENE; CENTCHROMAN; CLOMIFENE; CONJUGATED ESTROGEN; ESTROGEN DERIVATIVE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TISSUE SELECTIVE ESTROGEN COMPLEX; TOREMIFENE; UNCLASSIFIED DRUG;

AMENORRHEA; BONE MASS; BREAST CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MASTALGIA; MENOPAUSAL SYNDROME; OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AMENORRHEA; BONE DENSITY; BREAST; CLINICAL TRIALS, PHASE III AS TOPIC; ENDOMETRIUM; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; MULTICENTER STUDIES AS TOPIC; PAIN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78049468658     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/mi.2010.010033     Document Type: Review

References (43)

1. US Census Bureau. Midyear population, by age and sex. See http://www.census.gov/ipc/www/idb/region.php (last accessed 6 June 2010)
2. UK National Statistics. 2008-based national population projections. See www.statistics.gov.uk/downloads/theme-population/NPP2008/NatPopProj2008.pdf (last accessed 9 June 2010)
3. US Census Bureau. Percent distribution of the projected population by selected age groups and sex for the United States: 2010 to 2050. See http://www.censusgov/population/www/projections/summarytables.html (last accessed 9 June 2010)
4. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nur Health 1985;8:261-8
5. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Social Med 1974;28:115
6. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984-92
7. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86
8. Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009;16:453-7
9. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-18 (Pubitemid 35449187)
10. Pickar JH, Yeh I, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31 (Pubitemid 32600955)
11. Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-40
12. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32 (Pubitemid 26274121)
13. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging 2010;27:533-44
14. Pickar JH, MacNeil T, Ohleth K. SERMs: Progress and future perspectives. Maturitas 2010;67:129-38
15. Berrodin TJ, Chang KC, Komm BS, et al. Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009;23:74-85
16. Komm BS, Pickar JH. Tissue selective estrogen complex (TSEC): a new paradigm for menopausal therapy. In: IM Society. Complete proceedings collection of the 6th International Menopause Society workshop: Menopause and ageing, quality of life and sexuality. International Menopause Society: Pisa, 2006:1-12
17. Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
18. Nolvadex® (tamoxifen citrate) Prescribing Information. AstraZeneca
19. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971;25:270-5
20. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6
21. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37 (Pubitemid 29019045)
22. Zilli M, Grassadonia A, Tinari N, et al. Molecular mechanisms of endocrine resistance and their implications in the therapy of breast cancer. Biochim Biophys Acta 2009;1795:62-81
23. Evista® (raloxifene hydrochloride) Prescribing Information. Eli Lilly and Company
24. Evista® (raloxifene hydrochloride) Summary of Product Characteristics. Eli Lilly and Company
25. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52 (Pubitemid 41368577)
26. Fablyn® (lasofoxifene tartrate) Summary of Product Characteristics. Pfizer Inc
27. Fareston® (toremifene citrate) Tablets. GTx, Inc
28. Chang KC, Wang Y, Bodine PV, et al. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118:117-24
29. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-26
30. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008 (Pubitemid 41175771)
31. Crabtree JS, Peano BJ, Zhang X, et al. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 2008;287:40-6
32. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
33. Pickar JH, Yeh I-T, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
34. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009;92:1025-38
35. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
36. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
37. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-24
38. Wattanakumtornkul S, Chichareon S, Geater A, et al. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 2003;29:380-7 (Pubitemid 38180674)
39. Manonai J, Theppisai U, Suchartwatnachai C, et al. Compliance with hormone replacement therapy in Thai women. Maturitas 2003;44:201-5 (Pubitemid 36315816)
40. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7 (Pubitemid 32522601)
41. Stovall DW, Utian W, Gass M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-17
42. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. Menopause 2004;11:167-75 (Pubitemid 40353234)
43. Carranza-Lira S, Gooch AL, Saldivar N, et al. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007;52:93-6